IndustryCompany release

Ashland fourth-quarter sales rise 4% to $498M, led by pharma and personal care

🇺🇸 Ashland Inc. (ASH) · Tue 03 Nov 2026

The specialty ingredients maker reported Adjusted EBITDA of $121 million for the quarter to 30 September 2026 and issued fiscal 2027 guidance, despite a GAAP net loss.

Ashland Inc. reported fiscal fourth-quarter results on 3 November 2026 for the period ended 30 September 2026. Sales came to $498 million, which the company's headline describes as a 4% increase, and Adjusted EBITDA was $121 million.

Growth was led by the Life Sciences segment, which includes pharmaceutical excipients, and by Personal Care. The summary of the announcement does not give segment-level figures, so the size of each contribution is not known.

Ashland nonetheless posted a GAAP net loss of $16 million for the quarter. The information available does not explain what drove the loss or how it relates to the adjusted figures.

Looking ahead, the company guided fiscal 2027 sales of $1,905 million to $1,975 million and Adjusted EBITDA of $405 million to $435 million.

What it means for your team

  • Procurement and supplier-quality teams may note that Ashland's Life Sciences business, which includes pharma excipients, was cited as a growth driver in the quarter.
  • The announcement as summarised contains no information on product supply, quality issues or regulatory actions, so no operational impact can be inferred.
  • Market-access and sourcing teams can use the fiscal 2027 sales and Adjusted EBITDA ranges as a reference point for the supplier's financial outlook.

Company's press release (SEC filing): Ashland Inc. ↗

Article written by VigiEye from the official source (Ashland Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →